2 results
Approved WMOCompleted
The primary objective of the trial is to demonstrate non-inferiority of treatment with TMC278 when administered as 75 mg q.d. compared to the control group (EFV) in regard to the proportion of virologic responders (plasma viral load < 50 HIV-…
Approved WMOCompleted
Primary• To evaluate the safety and tolerability of single ascending IV doses of ANX105 in normal healthy participantsSecondary• To characterize the single-dose PD of ANX105• To characterize the single-dose PK of ANX105